Literature DB >> 29707278

Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?

Eirini Pectasides1,2.   

Abstract

Entities:  

Year:  2018        PMID： 29707278      PMCID： PMC5906259          DOI： 10.21037/jtd.2018.02.74

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

2.  Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Authors:  Toshihiro Kudo; Yasuo Hamamoto; Ken Kato; Takashi Ura; Takashi Kojima; Takahiro Tsushima; Shuichi Hironaka; Hiroki Hara; Taroh Satoh; Satoru Iwasa; Kei Muro; Hirofumi Yasui; Keiko Minashi; Kensei Yamaguchi; Atsushi Ohtsu; Yuichiro Doki; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

3.  Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Authors:  Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

5.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

6.  Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.

Authors:  Changsen Leng; Yin Li; Jianjun Qin; Jun Ma; Xianben Liu; Yingying Cui; Haibo Sun; Zongfei Wang; Xionghuai Hua; Yongkui Yu; Haomiao Li; Jun Zhang; Yan Zheng; Wei Wang; Junwei Zhu; Qiuming Wang
Journal:  Oncol Rep       Date:  2015-11-17       Impact factor: 3.906

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study.

Authors:  J Steevens; L J Schouten; R A Goldbohm; P A van den Brandt
Journal:  Gut       Date:  2010-01       Impact factor: 23.059

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.

Authors:  Kaiyan Chen; Guoping Cheng; Fanrong Zhang; Nan Zhang; Dan Li; Jiaoyue Jin; Junzhou Wu; Lisha Ying; Weimin Mao; Dan Su
Journal:  Oncotarget       Date:  2016-05-24
View more
  2 in total

1.  Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.

Authors:  Ting Yan; Heyang Cui; Yong Zhou; Bin Yang; Pengzhou Kong; Yingchun Zhang; Yiqian Liu; Bin Wang; Yikun Cheng; Jiayi Li; Shixing Guo; Enwei Xu; Huijuan Liu; Caixia Cheng; Ling Zhang; Ling Chen; Xiaofei Zhuang; Yu Qian; Jian Yang; Yanchun Ma; Hongyi Li; Fang Wang; Jing Liu; Xuefeng Liu; Dan Su; Yan Wang; Ruifang Sun; Shiping Guo; Yaoping Li; Xiaolong Cheng; Zhihua Liu; Qimin Zhan; Yongping Cui
Journal:  Nat Commun       Date:  2019-04-11       Impact factor: 14.919

Review 2.  Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma.

Authors:  Lehang Lin; De-Chen Lin
Journal:  Cancers (Basel)       Date:  2019-08-12       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.